INVESTMENTS TO ADDRESS HEALTH INEQUITIES IN PROSTATE CANCER CARE Movember funds three Australian programs targeting under-served populations
SEGMENT
Filmed in Melbourne | February 2025
INTERVIEWS
Sarah Weller
Global Director – Prostate Cancer, Movember
Kris Bennett,
Director – Prostate Cancer Health Equity, Movember
Movember is committed to advancing new research, cutting-edge treatments, and healthy behaviours, and advocating for inclusive, gender-responsive healthcare that caters to the unique needs of men, women, and gender-diverse individuals from diverse cultural backgrounds. In doing so, they hope to forge a future where barriers to healthy living are overcome, stigmas are removed, and where everyone has an equal opportunity to live a long, healthy life.
Income, education, geographical location, and discrimination based on ethnicity, race, gender and sexual orientation, are only a fraction of factors that can negatively affect a person’s quality of cancer care. This is defined as the “equity gap” and it’s costing people their lives.
Timed to coincide with World Cancer Day 4th February 2025, Movember announced prostate cancer investment of $5.5 million. Eighteen grants (16 proposals and 2 community development grants) are slated to directly tackle inequities in prostate cancer care. The funding will be over three years with the grants spread across five countries – six in Canada, five in the United Kingdom, three in Australia, three in the United States and one in Ireland – each having a specific focus population and care area.
AUSTRALIAN FUNDING FOR TARGETED PROSTATE CANCER CARE OUTREACH PROGRAMS
– The prostate cancer mortality rate in remote areas is almost 20% higher than in major cities. Access to treatment is the leading cause. This equity gap is what the Royal Flying Doctor Service of Australia’s grant will address, to improve access to and use of prostate cancer treatment services in rural and remote areas.
– Currently, prostate cancer data on the culturally and linguistically diverse communities of South Western Sydney is insufficient. That’s the first roadblock to improving this historically overlooked group’s prostate cancer care. The George Institute for Global Health aims to fill in the blanks with population level data to help close this equity gap.
– Australian Prostate Centre will create culturally appropriate prostate cancer services and practices for the LGBTQIA+ community, to counter the fear of discrimination and stigma that often stands in its way of getting prostate cancer screenings and diagnoses.
Australian Health Journal spoke with Movember about these targeted outreach programs in Australia and the hope they will help provide education and empower historically and intentionally excluded communities, using community stakeholders and voices to build trust. Collaborations with healthcare providers, academic institutions, and community-based organisations will share resources and expertise to develop tailored solutions.
-
Sovereign capability uplifted
Skilled labour, in particular skilled in the manufacture of MTP products, namely competency in Good Manufacturing Practice (GMP), was identified as one of the key priorities, according to Jarrod Belcher, Director of the REDI Program at MTPConnect. Through a competitive process, MTPConnect selected additional industry training providers to deliver new programs addressing key skills gaps in the sector workforce.
Launched in September 2022, one of these programs is GMP Uplift developed by the Centre for Biopharmaceutical Excellence (CBE). CBE bring experience across large and small Biologics, Pharmaceuticals and Regenerative Medicine companies, both in consulting and GMP related enterprise training. CBE staff also have extensive experience in GMP operations, compliance, auditing and QMS design, a wide industry network for guest lecturers and readily available case studies.
-
Developing the nation’s first Health and Medical Research Strategy
Professor Steve Wesselingh serves as the CEO of NHMRC, having initially trained as an infectious diseases doctor. His career includes prominent roles such as Head of the Infectious Diseases Unit at the Alfred Hospital, Director of the Burnett, Dean of Medicine at Monash University, and the inaugural Director of SAHMRI. Under his leadership, NHMRC plays a critical role in funding health and medical research, allocating approximately a billion dollars annually to investigator-led projects, clinical trials, and various strategic initiatives. NHMRC also collaborates internationally with organisations such as the MRC and the EU, and manages grant allocation for the MRFF, which distributes $650 million each year.
-
Artificial Intelligence (AI) in clinical trials and clinical care
Australian Health Journal today continues a major episode release on Technology Aided Healthcare Delivery, with part 2 on Artificial Intelligence in trials and clinical care. Interviews were captured at AI, Machine Learning & Robotics in Health conference in October organised by Informa Australia.
